Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 108 | NANETS2024 | Next issue

NANETS 2024

17th Annual Multidisciplinary NET Medical Symposium NANETS 2024

Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Previous section
Clinical - Chemo/SSA/Biologics
Table of contents
Next section
Clinical - Surgery/Applied Pathology

ea0108c20 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Imaging, clinical, and safety outcomes in metastatic neuroendocrine tumor patients treated with peptide receptor radionuclide therapy in the midwestern USA

ea0108c21 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Effect of absorbed dose on toxicity and tumor response of Lu-177-DOTATATE with olaparib in gastroenteropancreatic neuroendocrine patients: preliminary results

ea0108c22 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Multicenter clinical registry of patients with a neuroendocrine tumor (NET) diagnosis receiving Lu-177-DOTATATE

ea0108c23 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Neuroendocrine tumor (NET) progression of disease during or within one year after completion of therapy with Lu-177-DOTATATE

ea0108c24 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Evaluating time to treatment start for patients receiving peptide receptor radioligand therapy

ea0108c25 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Does liver tumor morphology predict outcomes after LDT, PRRT or captem?

ea0108c26 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Incidence and characterization of carcinoid crises post embolization of neuroendocrine tumor liver metastases

ea0108c27 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive metastases

ea0108c28 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Liver-directed therapy for metastatic neuroendocrine carcinoma and grade 3 well-differentiated neuroendocrine tumors

ea0108c29 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Initial outcomes of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 3 liver-dominant metastatic neuroendocrine tumors

ea0108c30 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis of expression in the era of somatostatin receptor PET imaging

ea0108c31 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

First-line efficacy of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: phase 3 NETTER-2 subgroup analysis

ea0108c32 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with malignant pheochromocytoma (PCC) and paraganglioma (PGL): a single institution retrospective study

ea0108c33 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Corticosteroid prophylaxis did not decrease tumor flare reaction in high-risk neuroendocrine tumors patients treated with 177Lu-DOTATATE

ea0108c34 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Peptide receptor radionuclide therapy with 177 Lu-DOTATATE: a single center experience

ea0108c35 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Small bowel obstruction incidence in Lu177 PRRT patients had no impact on overall survival

ea0108c36 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Safety and efficacy of peptide receptor radionuclide therapy in thymic neuroendocrine neoplasms: a single-institutional case series

ea0108c37 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

ea0108c38 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Radioactivity in drained body cavity fluid following peptide receptor radionuclide therapy with 177Lu DOTATATE in patients with advanced neuroendocrine tumors

ea0108c39 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Dosimetry-guided 131I-mIBG therapy in a hemodialysis-dependent paraganglioma patient

ea0108c40 | Clinical - Nuclear Medicine/Interventional Radiology/Imaging

Implementation of dosimetry in clinical Lu177-DOTATATE therapy

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more